<?xml version="1.0" encoding="UTF-8"?>
<p>The presented results are based on a secondary analysis of previously published data from the IRIS (
 <italic>
  <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link> identifier: 00006343
 </italic>)
 <sup>
  <xref rid="b18-1031825" ref-type="bibr">18</xref>
 </sup> and CML IV (
 <italic>
  <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link> identifier: 00055874
 </italic>) trials.
 <sup>
  <xref rid="b19-1031825" ref-type="bibr">19</xref>
 </sup> In particular, we used 69 patients from the German imatinib (400 mg) arm of the IRIS trial and 280 patients from the 400 mg imatinib monotherapy arm of the CML-IV study, for which IS corrected 
 <italic>BCR-ABL1/ABL1</italic> time courses were available at the time of our primary model analysis.
 <sup>
  <xref rid="b5-1031825" ref-type="bibr">5</xref>,
  <xref rid="b17-1031825" ref-type="bibr">17</xref>
 </sup> As described in the original publications,
 <sup>
  <xref rid="b20-1031825" ref-type="bibr">20</xref>,
  <xref rid="b21-1031825" ref-type="bibr">21</xref>
 </sup> both clinical trials were conducted in accordance with the Declaration of Helsinki and applicable regulatory requirements. The protocols were approved by the institutional review board or ethics committee of each participating center. All patients or guardians gave written informed consent before participation.
</p>
